盐酸哌甲酯控释片治疗注意缺陷多动障碍研究进展被引量：3

Treatment of children and adolescents with attention deficit/hyperactivity disorder with methylphenidate hydrochloride

下载PDF

导出

摘要注意缺陷多动障碍是一种儿童期常见的精神障碍,中枢兴奋剂如盐酸哌甲酯片是临床治疗此类障碍的一线药物。然而,由于盐酸哌甲酯片疗效持续时间较短,需要每天多次服药使治疗依从性不佳。盐酸哌甲酯控释片(专注达)是每天1次服用的渗透型控释片剂,成为治疗注意缺陷多动障碍的有价值药物。现综述其药动学、药理作用、剂型特点、临床疗效和安全性研究进展。 Attention deficit/hyperactivity disorder （ADHD） is one of the most prevalent child- hood psychiatric disorders. Stimulant medications are among the first-line agents in the pharmacotherapy of ADHD. Of the stimulant medications, methylphenidate （MPH） is the most studied. Compared with immediate-release （IR） MPH with a short duration of action requiring multiple daily dosing, which creates significant problems in the compliance of schools, parents/caregivers, and children, extended-release stimulant preparations have become a favorable pharmacological treatment for ADHD. OROS MPH （CONCERTA） is a once-daily, osmotic, controlled-release tablet of MPH. This review discussed the pharmacology, clinical effectiveness and safety of the controlled-release tablets of methylphenidate hydrochloride.

作者崔永华郑毅

机构地区首都医科大学附属北京安定医院十一区

出处《中国新药杂志》 CAS CSCD 北大核心 2006年第20期1731-1734,1784,共5页 Chinese Journal of New Drugs

关键词注意缺陷多动障碍盐酸哌甲酯控释制剂 attention deficit/hyperactivity disorder （ADHD） methylphenidate hydroehloride delayed-action preparations

分类号 R971.7 [医药卫生—药品]

引文网络
相关文献

参考文献23

1SHMUELI D,GROSS-TSUR V.Attention deficit hyperactivity disorder:pharmacological options that are not "Ritalin"[J].Harefuah,2005,144(8):572-576,597.
2GONZALEZ MA,PENTIKIS HS,ANDERL N,et al.Methylphenidate bioavailability from two extended-release formulations[J].Int J Clin Pharmacol Ther,2002,40(4):175-184.
3MARKOWITZ JS,STRAUGHN AB,PATRICK KS,et al.Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults[J].Clin Pharmacokinet,2003,42 (4):393-401.
4WOLRAICH ML,DOFFING MA.Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate[J].CNS Drugs,2004,18(4):243-50.
5PELHAM WE,GNAGY EM,BURROWS-MACLEAN L,et al.Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings[J].Pediatrics,2001,107(6):E105.
6COX DJ,MERKEL RL,PENBERTHY JK,et al.Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder:a pilot study[J].J Am Acad Child Adolesc Psychiatry,2004,43(3):269-275.
7WOLRAICH ML,GREENHILL LL,PELHAM W,et al.Randomized,controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder[J].Pediatrics,2001,108(4):883-892.
8MARCUS SC,WAN GJ,KEMNER JE,et al.Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder[J].Arch Pediatr Adolesc Med,2005,159 (6):572-578.
9LAGE M,HWANG P.Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment[J].J Child Adolesc Psychopharmacol,2004,14(4):575-581.
10WILENS TE,MCBURNETT K,BUKSTEIN O,et al.multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder[J].Arch Pediatr Adolesc Med,2006,160 (1):82-90.

二级参考文献13

1Elia J. Drug treatment for hyperactive children:therapeutic guidelines. Drugs, 1993, 46:863-871.
2Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am, 1992, 15:1-27.
3Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry, 1996, 35:409-432.
4Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in aggressive-hyperactive boys: I.effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry, 1990, 29:710-718.
5Hoffman BB, Lefkowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor antagonists. In: Hardman J, Limbird L, Molinoff P, eds. Goodman and gilman's the pharmacological basis of therapeutics. 9th ed. New York: MacMillan Publishing, 1996. 199-248.
6Wolraich ML, Doffing MA.Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs, 2004, 18:243-250.
7Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther, 2002, 40:175-184.
8Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet, 2003, 42:393-401.
9Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics, 2004,113(3 Pt 1):e206-216.
10Lopez F, Silva R, Pestreich L, et al. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs, 2003, 5:545-555.